BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., LTD.

百奧賽圖(北京)醫藥科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2315)

VOLUNTARY ANNOUNCEMENT

SHARE REPURCHASE AND ESTABLISHMENT OF TRUST; AND

PURCHASE OF SHARES FOR SHARE AWARD SCHEME

This announcement is made by Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis to allow the shareholders of the Company (the "**Shareholder(s)**") to understand the latest information of the Group.

Reference is made to the circular dated April 23, 2025 in relation to the 2024 annual general meeting (the "**AGM Circular**") and the announcement dated May 28, 2025 (the "**AGM Poll Results Announcement**") of the Company. Unless the context otherwise requires, capitalised terms defined herein shall have the same meanings as those defined in the AGM Circular and the AGM Poll Results Announcement.

As disclosed in the AGM Poll Results Announcement, the Shareholders approved by way of a special resolution at the AGM the repurchase by the Company of up to 11,078,192 H Shares (excluding Treasury Shares) under the Repurchase Mandate during the Relevant Period, representing 10% of the total number of H Shares in issue and approximately 2.77% of the Company's total issued share capital as at the date of the AGM (excluding any Treasury Shares). The Company intends to purchase and/or repurchase H Shares using internal funds of not more than HK$50 million within the next 24 months. The Company may cancel such repurchased Shares or hold them as Treasury Shares (in relation to the repurchase of H Shares) and shall use the purchased H Shares to satisfy the share awards (in relation to the purchase of H Shares for the employees' share award scheme adopted by the Company on November 22, 2022 (the "**Share Award Scheme**")), subject to market conditions and the Group's capital management needs at the relevant time of the purchases and/or repurchases.

For the purpose of the share repurchase, the Company proposes to appoint Kastle Limited as the trustee to establish a bare trust (the "**Trust**") for the purpose of holding the H Shares repurchased by the Company as Treasury Shares for management. Meanwhile, the Company has instructed CMB Wing Lung (Trustee) Limited to manage the Share Award Scheme and purchase H Shares for satisfaction of share awards.

In exercising the Repurchase Mandate, the Company undertakes to strictly comply with Chapter 10 of the Listing Rules, the Articles of Association, the Codes on Takeovers and Mergers and Share Buy-backs, the PRC Company Law, and other applicable laws and regulations. The Company will make the repurchase decision and implement the same as and when appropriate during the Relevant Period with reference to market conditions, and fulfill the information disclosure obligations in a timely manner based on the progress of the share repurchase.

Shareholders and potential investors of the Company should note that any repurchase of H Shares that may be made under the share repurchase plan is subject to market conditions and will be made at the absolute discretion of the Board. There is no assurance as to the timing, quantity or price of any share repurchase. Accordingly, Shareholders and potential investors of the Company are advised to exercise caution when dealing in the Shares.

By order of the Board
Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
Shen Yuelei
Chairman of the Board, Chief Executive Officer and Executive Director

Hong Kong, June 13, 2025

As at the date of this announcement, the Board comprises Dr. Shen Yuelei as chairman, chief executive officer and executive director, Dr. Ni Jian and Dr. Zhang Haichao as executive directors; Mr. Wei Yiliang, Dr. Zhou Kexiang and Ms. Zhang Leidi as non-executive directors; Mr. Hua Fengmao, Dr. Yu Changyuan and Ms. Liang Xiaoyan as independent non-executive directors.